Asia
Last year, AmoyDx’s EGFR diagnostic was approved for use in the EU.
Clover Biopharma announced plans to build a biologic drug manufacturing facility in Changxing, Zhejiang Province.
Another experimental Alzheimer’s disease treatment has failed in a late-stage study.
This acquisition strategy is part of its two-pronged approach to growth, along with internal R&D.
The company’s Luye Medical Group unit plans to evaluate proposals from investment banks as soon as next month, according to the people.
The latest funding round gives XtalPi $20M in the bank, which the company said makes it “one of the top-funded AI-powered biotechs.”
China researchers have treated 86 cancer patients with genetically modified versions of their own immune cells.
Sinocare of Changsha may bid as much as $4B to acquire J&J’s diabetes medical device subsidiaries
The company will use the money to fund clinical trials and develop a marketing operation.
Celltrion, the little-known South Korean biotech company that surged into the ranks of the world’s most-traded stocks at the start of 2018, may finally be coming down to Earth.
PRESS RELEASES